全文获取类型
收费全文 | 110714篇 |
免费 | 8582篇 |
国内免费 | 5065篇 |
专业分类
耳鼻咽喉 | 255篇 |
儿科学 | 3287篇 |
妇产科学 | 688篇 |
基础医学 | 7643篇 |
口腔科学 | 281篇 |
临床医学 | 9316篇 |
内科学 | 62938篇 |
皮肤病学 | 434篇 |
神经病学 | 2091篇 |
特种医学 | 2285篇 |
外国民族医学 | 15篇 |
外科学 | 8963篇 |
综合类 | 7014篇 |
现状与发展 | 16篇 |
一般理论 | 4篇 |
预防医学 | 3809篇 |
眼科学 | 140篇 |
药学 | 6895篇 |
71篇 | |
中国医学 | 510篇 |
肿瘤学 | 7706篇 |
出版年
2024年 | 123篇 |
2023年 | 3132篇 |
2022年 | 4884篇 |
2021年 | 5807篇 |
2020年 | 5109篇 |
2019年 | 3711篇 |
2018年 | 4569篇 |
2017年 | 4016篇 |
2016年 | 3959篇 |
2015年 | 4300篇 |
2014年 | 8037篇 |
2013年 | 7352篇 |
2012年 | 7069篇 |
2011年 | 7095篇 |
2010年 | 6035篇 |
2009年 | 5337篇 |
2008年 | 4787篇 |
2007年 | 4991篇 |
2006年 | 4490篇 |
2005年 | 3899篇 |
2004年 | 3103篇 |
2003年 | 3001篇 |
2002年 | 2647篇 |
2001年 | 2376篇 |
2000年 | 1913篇 |
1999年 | 1709篇 |
1998年 | 1083篇 |
1997年 | 710篇 |
1996年 | 801篇 |
1995年 | 838篇 |
1994年 | 648篇 |
1993年 | 596篇 |
1992年 | 687篇 |
1991年 | 643篇 |
1990年 | 664篇 |
1989年 | 600篇 |
1988年 | 560篇 |
1987年 | 419篇 |
1986年 | 313篇 |
1985年 | 249篇 |
1984年 | 222篇 |
1983年 | 166篇 |
1982年 | 196篇 |
1981年 | 153篇 |
1980年 | 137篇 |
1979年 | 139篇 |
1978年 | 153篇 |
1977年 | 143篇 |
1976年 | 104篇 |
1975年 | 103篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
91.
目的 探讨扶正消瘤颗粒对原发性肝癌血清中血管内皮生长因子(Vascular endothelial growth factor,VEGF)和缺氧诱导因子-1α(Hypoxia inducible factor-1α,HIF-1α)表达的影响及临床意义。方法 选择符合纳入标准的原发性肝癌患者66例,按1∶1随机分试验组和对照组。观察治疗过程中两组VEGF、HIF-1α水平的变化及对患者临床疗效指标的影响。结果 (1)在性别、年龄、合并乙型肝炎、Child-Pugh分级、AFP值、临床分期方面,试验组和对照组差异无统计学意义(P > 0.05)。(2)肝癌患者在治疗各时间节点的VEGF和HIF-1α表达水平呈线性正相关(r = 0.829,P < 0.001)。(3)VEGF浓度在经导管动脉化疗栓塞术(Transcatheter arterial chemoembolization,TACE)后3月降至术前水平(P > 0.05),HIF-1α在TACE后3月仍高于术前(P < 0.05)。(4)扶正消瘤颗粒可降低HIF-1α水平,下调VEGF的表达。(5)扶正消瘤颗粒可减少TACE序贯RFA治疗后的不良反应,提高患者的生活质量(P < 0.05)。(6)血清中VEGF水平与生活质量无明显相关性(P > 0.05,r = 0.251),HIF-1α水平与生活质量存在正相关性(P < 0.05,r = 0.450)。结论 扶正消瘤颗粒可明显改善TACE序贯RFA治疗后患者生活质量,降低HIF-1α水平,下调VEGF的表达,抑制肿瘤血管生成。 相似文献
92.
ObjectivesTo assess consumption of dietary and herbal supplements (DHS) among patients in internal medicine departments and determine whether such use is documented in their medical files.Methods267 patients from three internal medicine departments of an academic medical center in Haifa, Israel were assessed prospectively with questionnaires about their DHS use in the month preceding hospitalization. DHS were categorized into vitamins & minerals, herbal supplements and others. Further data was then collected from patients' medical records on socio-demographic and medical characteristics, as well as documentation of DHS use.Results123 patients (50.6 %) used DHS on a daily basis. Most of them (53.7 %) were using more than one DHS. DHS use was more prevalent in older (OR = 1.02 [1.001–1.036], p = 0.034) and educated (OR = 0.482 [0.252-0.923], p = 0.028) patients. Vitamins & minerals were used mainly to enhance vitality and address laboratory abnormalities, whereas herbal supplements were used mainly for gastrointestinal problems (p < 0.001). DHS use was reported to the physicians by 42 % of the patients, mostly at the patients’ initiative [92 (82.1 %), p < 0.001)]. Vitamins and minerals were the most reported category of DHS (94 (57.3 %), p < 0.001). The use of DHS was reported to physicians for 112 DHS (41.8 %) but only 32 DHS (11.9 %) were documented in their medical files. The documentation of vitamins and minerals was significantly higher compared to herbal supplements documentation (29 (17.7 %) & 3 (2.9 %) respectively, P < 0.001).ConclusionsDHS are commonly used by patients hospitalized in the internal medicine departments. Many patients do not report such use to the physicians, and more strikingly, physicians do not document DHS use in patient medical files. This communication gap may have serious medico-legal ramifications due to DHS side effects and DHS interactions with other DHS and with conventional drugs. 相似文献
93.
《Transplantation reviews (Orlando, Fla.)》2022,36(2):100686
Kidney transplantation has evolved over the years from transplants between identically matched donors and recipients to successfully transplanting allografts across virtually any degree of donor-recipient human leukocyte antigen mismatch and ABO-incompatibility. Integral to these improved outcomes has been the development and deployment of a range of immunosuppressive agents. The addition of monoclonal and polyclonal antibodies as a standard part of overall immunosuppression has led to the improved outcomes by providing a robust and focused protection during the first few months of transplantation when allografts are most vulnerable to immune-mediated injury.Alemtuzumab is a recombinant anti-CD52 pan-lymphocyte depleting monoclonal antibody that has been in use for kidney transplantation since the late 1990s.Despite the many years of experience with alemtuzumab, its utilisation in the UK has remained relatively restrained. This may be due to a lack of high-level evidence to support its safety and efficacy in transplantation. Also, long-term outcomes have not been addressed by existing studies.Nevertheless, available evidence suggests that alemtuzumab is associated with a lower risk of acute rejection within the first year of transplantation while exhibiting a comparable safety profile to non-lymphocyte depleting agents. Despite the current economic advantages of alemtuzumab (available free of cost on a named transplant recipient basis), its use in UK transplant centres has remained limited, variating from non-use, through usage in selected high immunologic risk subjects, to use as routine induction immunosuppression.This review discusses the current use of alemtuzumab for immunosuppression induction in kidney transplantation. It describes its evolution from development to its present application in kidney transplantation and reviews the evidence underpinning its utilisation. The role of alemtuzumab in the immunosuppressive protocols individual UK kidney transplant centres is also described. 相似文献
94.
95.
96.
97.
98.
99.
100.